Income Statement

v3.19.2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
REVENUES        
Real property rental $ 264,889 $ 278,872 $ 531,515 $ 575,495
Medical related consulting services - related party 111,434 141,996 125,694 141,996
Development services and sales of developed products 23,404 75,225 26,682 86,515
Total Revenues 399,727 496,093 683,891 804,006
COSTS AND EXPENSES        
Real property operating expenses 192,676 195,941 423,435 406,215
Medical related consulting services - related party 95,375 124,715 108,466 124,715
Development services and sales of developed products 31,784 42,093 62,091 58,613
Total Costs and Expenses 319,835 362,749 593,992 589,543
REAL PROPERTY OPERATING INCOME 72,213 82,931 108,080 169,280
GROSS PROFIT FROM MEDICAL RELATED CONSULTING SERVICES 16,059 17,281 17,228 17,281
GROSS (LOSS) PROFIT FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS (8,380) 33,132 (35,409) 27,902
OTHER OPERATING EXPENSES:        
Advertising expenses 221,222 465,822
Compensation and related benefits 2,100,178 487,452 4,200,333 1,026,266
Professional fees 792,486 593,025 2,260,712 1,164,797
Research and development expenses 949,711 263 1,102,171 263
Other general and administrative 360,047 265,858 869,926 551,110
Total Other Operating Expenses 4,423,644 1,346,598 8,898,964 2,742,436
LOSS FROM OPERATIONS (4,343,752) (1,213,254) (8,809,065) (2,527,973)
OTHER INCOME (EXPENSE)        
Interest income 433 1,300 1,201 1,708
Interest expense (8,822) (24,932) (34,519) (261,918)
Interest expense - related party (12,639) (14,583)
Change in fair value of warrants liability 461,493 461,493  
Financing expense (525,418) (525,418)
Loss from equity-method investment (10,344) (23,087)
Foreign currency transaction loss (106,929) (106,929)
Other income 226 226 328
Total Other Expense, net (95,071) (130,561) (134,687) (366,811)
LOSS BEFORE INCOME TAXES (4,438,823) (1,343,815) (8,943,752) (2,894,784)
INCOME TAXES
NET LOSS (4,438,823) (1,343,815) (8,943,752) (2,894,784)
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST (81,599) (49,421) (180,712) (118,811)
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS (4,357,224) (1,294,394) (8,763,040) (2,775,973)
COMPREHENSIVE LOSS:        
NET LOSS (4,438,823) (1,343,815) (8,943,752) (2,894,784)
OTHER COMPREHENSIVE INCOME        
Unrealized foreign currency translation gain (loss) (34,103) (96,207) 9,379 (43,369)
COMPREHENSIVE LOSS (4,472,926) (1,440,022) (8,934,373) (2,938,153)
LESS: COMPREHENSIVE GAIN (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTEREST (79,699) (49,540) (180,010) (118,770)
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS $ (4,393,227) $ (1,390,482) $ (8,754,363) $ (2,819,383)
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:        
Basic and diluted $ (0.06) $ (0.02) $ (0.12) $ (0.04)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic and diluted 75,183,354 71,979,678 74,437,336 71,122,356

Source